PAR-1 inhibitors: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(5 intermediate revisions by one other user not shown)
Line 1: Line 1:
Protease Activated Receptor ('''PAR''')-'''1''' '''inhibitors''' (also known as thrombin receptor antagonists) are a new class of antiplatelet agents that '''antagonize platelet activation mediated by thrombin''', the most potent platelet activator.  
{{SI}}
 
'''Editors-In-Chief:''' Sergio Leonardi, M.D., Duke Clinical Research Institute; [[C. Michael Gibson]], M.S., M.D.
 
==Overview==
Protease Activated Receptor ('''PAR''')-'''1''' '''inhibitors''' (also known as thrombin receptor antagonists, TRAs) are a new class of antiplatelet agents that '''antagonize platelet activation mediated by thrombin''', the most potent platelet activator.  
 
The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR.  
The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR.  
The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation.
The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation.
The 2 agents in most advanced clinical development are [[vorapaxar]] (previously known as SCH530348) and [[atopaxar]] (previously known as E-5555).
The 2 agents in most advanced clinical development are '''[[vorapaxar]]''' (previously known as SCH530348) and '''[[atopaxar]]''' (previously known as E-5555).
 
{{WH}}
{{WS}}

Latest revision as of 13:23, 26 October 2010

WikiDoc Resources for PAR-1 inhibitors

Articles

Most recent articles on PAR-1 inhibitors

Most cited articles on PAR-1 inhibitors

Review articles on PAR-1 inhibitors

Articles on PAR-1 inhibitors in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on PAR-1 inhibitors

Images of PAR-1 inhibitors

Photos of PAR-1 inhibitors

Podcasts & MP3s on PAR-1 inhibitors

Videos on PAR-1 inhibitors

Evidence Based Medicine

Cochrane Collaboration on PAR-1 inhibitors

Bandolier on PAR-1 inhibitors

TRIP on PAR-1 inhibitors

Clinical Trials

Ongoing Trials on PAR-1 inhibitors at Clinical Trials.gov

Trial results on PAR-1 inhibitors

Clinical Trials on PAR-1 inhibitors at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on PAR-1 inhibitors

NICE Guidance on PAR-1 inhibitors

NHS PRODIGY Guidance

FDA on PAR-1 inhibitors

CDC on PAR-1 inhibitors

Books

Books on PAR-1 inhibitors

News

PAR-1 inhibitors in the news

Be alerted to news on PAR-1 inhibitors

News trends on PAR-1 inhibitors

Commentary

Blogs on PAR-1 inhibitors

Definitions

Definitions of PAR-1 inhibitors

Patient Resources / Community

Patient resources on PAR-1 inhibitors

Discussion groups on PAR-1 inhibitors

Patient Handouts on PAR-1 inhibitors

Directions to Hospitals Treating PAR-1 inhibitors

Risk calculators and risk factors for PAR-1 inhibitors

Healthcare Provider Resources

Symptoms of PAR-1 inhibitors

Causes & Risk Factors for PAR-1 inhibitors

Diagnostic studies for PAR-1 inhibitors

Treatment of PAR-1 inhibitors

Continuing Medical Education (CME)

CME Programs on PAR-1 inhibitors

International

PAR-1 inhibitors en Espanol

PAR-1 inhibitors en Francais

Business

PAR-1 inhibitors in the Marketplace

Patents on PAR-1 inhibitors

Experimental / Informatics

List of terms related to PAR-1 inhibitors

Editors-In-Chief: Sergio Leonardi, M.D., Duke Clinical Research Institute; C. Michael Gibson, M.S., M.D.

Overview

Protease Activated Receptor (PAR)-1 inhibitors (also known as thrombin receptor antagonists, TRAs) are a new class of antiplatelet agents that antagonize platelet activation mediated by thrombin, the most potent platelet activator.

The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. The 2 agents in most advanced clinical development are vorapaxar (previously known as SCH530348) and atopaxar (previously known as E-5555).

Template:WH Template:WS